Polypid Ltd. Stock Price, News & Analysis

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the 14th Israel Controlled Release Society (ICRS) Conference. The company's Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs, Dalit Hazan, will deliver a presentation titled "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" on September 7, 2025.

The presentation is scheduled for 5:25 PM - 5:45 PM local time at the Enjoy Hotel, Dead Sea, Israel, as part of Session 1 on "Advances in Targeted and Controlled Drug Delivery."

PolyPid (NASDAQ:PYPD) announced significant milestones in Q2 2025, highlighted by positive Phase 3 SHIELD II trial results for D-PLEX₁₀₀. The trial demonstrated a 58% reduction in surgical site infections (SSIs) and met its primary efficacy endpoint with a 38% reduction (p<0.005).

Key developments include plans for NDA submission in Q1 2026, unveiling of a novel long-acting GLP-1 delivery platform for obesity and diabetes, and appointment of Dr. Nurit Tweezer-Zaks as CMO. The company reported a Q2 2025 net loss of $10.0 million ($0.78 per share) and strengthened its balance sheet through warrant exercises, extending cash runway into 2026 with $29.5 million in cash and equivalents.

PolyPid (NASDAQ:PYPD), a late-stage biopharma company, has appointed Dr. Nurit Tweezer-Zaks as Chief Medical Officer, effective August 18, 2025. Dr. Tweezer-Zaks will transition from her current role on PolyPid's Board of Directors, which she has held since November 2023.

The appointment follows positive Phase 3 SHIELD II trial results and comes at a crucial time as the company prepares for its New Drug Application (NDA) submission. Dr. Tweezer-Zaks brings significant experience from her roles as CEO of MediCane Health Inc., CMO at aMOON Venture Capital Fund, and various positions at Sanofi, along with 15 years as a practicing physician at Sheba Medical Center.

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has scheduled its second quarter 2025 financial results announcement for August 13, 2025, before U.S. markets open.

The company will host a conference call and webcast at 8:30 AM Eastern Time to discuss quarterly results and provide business updates. Management recommends participants register at least 5 minutes before the call, with a webcast option available for those not planning to ask questions.

PolyPid (Nasdaq: PYPD) has unveiled a breakthrough long-acting GLP-1 receptor agonists delivery platform targeting diabetes and weight loss markets. The company's proprietary technology enables subcutaneous GLP-1 delivery for approximately 60 days, significantly improving upon current weekly injection standards.

The platform features linear drug release, addressing burst release issues common in weekly delivered molecules. The technology utilizes a polymer-lipid based matrix creating a protected drug reservoir, and has been clinically validated in over 1,000 patients including two Phase 3 trials with no major safety concerns. This expansion targets a market projected to reach $100 billion by 2030.

PolyPid has secured $26.7 million in funding through warrant exercises following positive Phase 3 SHIELD II trial results for D-PLEX₁₀₀, which demonstrated significant reduction in surgical site infections. The funding involves the immediate exercise of 7,626,514 warrants at $3.50 per share from existing warrant holders. In exchange, PolyPid will issue new unregistered warrants for the same number of shares, exercisable at $4.50 per share for two years. The company plans to use the proceeds for NDA submission, launch preparations, and working capital. This funding is expected to extend PolyPid's runway beyond the anticipated FDA approval of D-PLEX₁₀₀. The transaction is expected to close around June 18, 2025.

PolyPid announced positive topline results from its Phase 3 SHIELD II trial for D-PLEX100, demonstrating significant reduction in surgical site infections (SSIs) in abdominal colorectal surgery patients. The trial met its primary endpoint with a 38% reduction in combined SSIs, mortality, and surgical reinterventions (10.9% vs 18.1%, p<0.005). Key secondary endpoints were also met, including a 58% reduction in SSI rates (3.8% vs 9.5%, p<0.005) and a 62% reduction in ASEPSIS scores. The drug, which targets a U.S. market of over 12 million annual surgeries, showed no safety concerns. PolyPid plans to submit an NDA to the FDA in early 2026, followed by an MAA in the EU.

PolyPid Ltd. (PYPD) has announced a conference call and webcast scheduled for Monday, June 9, 2025, at 8:30 AM ET to discuss topline results from their SHIELD II Phase 3 trial. The trial evaluates D-PLEX100, their candidate for preventing surgical site infections in abdominal colorectal surgery patients. The company, which focuses on improving surgical outcomes, recommends participants register at least 5 minutes before the call's start time. The event will be accessible via both conference call and webcast formats.

PolyPid (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, has announced its participation in the upcoming Lytham Partners Spring 2025 Investor Conference. The virtual event will take place on May 29, 2025.

The company will deliver a webcast presentation at 10:15 a.m. ET and conduct one-on-one meetings with investors throughout the event. The presentation will be accessible through the conference website and will be available for replay after the event.